Home Analyst Ratings Sage Therapeutics Inc. gets an upgrade to a Buy from Guggenheim

Sage Therapeutics Inc. [SAGE] gets an upgrade to a Buy from Guggenheim

Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE]‎‎ rating to the equivalent of Buy from ‎Neutral, ‎in a research note dated January 4, 2021. Other analysts also revised their coverage, with ‎Mizuho’s analysts upgrading the shares from “a ‎Neutral” rating to “a Buy” rating in a research note to ‎investors issued in early December. Meanwhile, ‎Raymond James had lowered its rating on SAGE to ‎‎”Mkt perform” from the earlier “an Outperform”, in ‎a research note produced for clients December ‎‎01, 2020. In addition, there was a downgrade from ‎Morgan Stanley on November 16, 2020. The rater ‎changed SAGE from “an Overweight” to “an Equal-‎weight”.

Get the ‎hottest stocks to trade every day before the market ‎opens 100% free. Click here ‎now. ‎‎

Is Sage Therapeutics Inc. [NASDAQ:SAGE] a Good Buy Right ‎Now?

It should be noted that ‎SAGE technical indicators for short, intermediate as well as long ‎term progress have placed an overall ‎average of 100% as Buy. The average signal changed from 100% ‎Buy in the last week and compares ‎with 88% Buy in the past month. Data from Sage Therapeutics Inc.’s ‎Trend Spotter indicated that the ‎signals were Weakest. The stock current average is 0.65 million shares ‎in the past 20 days and the short ‎term average signal indicates a 100% Buy. In the last 50 days, the ‎average trading volume was 0.72 ‎million shares while the medium term average advocated for 100% ‎Buy. The average long-term signal ‎stands at 100% Buy and the 100-day average volume stands at 0.7 ‎million shares.‎‎


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


SAGE Price Performance

On Wall Street, Sage Therapeutics Inc. ‎‎[NASDAQ:SAGE] finished ‎Thursday’s session down -2.42% at $86.51. The stock went up to $89.16 at the ‎same session while its ‎lowest single day price was $86.25. In the last five days, it saw a fall of about -‎‎2.45%, Sage Therapeutics ‎Inc. shares gained by almost 19.84% since the beginning of the year. ‎However, the share price has ‎dropped to as low as -4.49% below its one year high. On 12/28/20, the ‎company shares recorded ‎‎$90.58, the highest single-day price it has got to in the last 52-weeks and a ‎‎52-week low was seen on ‎‎03/18/20, the same year at $25.01. The company’s shares have inclined by ‎‎18.25% in the past year. The ‎‎50-day SMA achieved is $76.25 while the 200-day SMA is $52.54. Volume ‎dropped to 0.29 million from ‎‎0.34 million in the previous session.‎‎

SAGE Stock Support And ‎Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 85.45 level, ‎and in case of violation of this particular level, it will cause more drop to ‎‎84.40 level. On the upper level, ‎‎90.22 is still the key resistance. The stock may increase to the ‎subsequent resistance at 88.36. The ‎Relative Strength Index (RSI) pinned on the 14-day chart is 64.36, ‎implying a neutral technical stance ‎while the MACD stands at 5.70, meaning price will increase in the ‎next trading period. Percent R ‎indicator moved to 18.03%, implying bullish price movement. Stochastic ‎‎%K at 86.10% suggest selling ‎the stock.‎‎

What is the short interest in Sage Therapeutics Inc.?

Short interest in the Sage ‎Therapeutics ‎Inc. stock has surged, increasing by 40000.0 shares to total 5.31 million shares on Dec 14, ‎‎2020. The ‎interest had seen shares on Nov 12, 2020 stand at 5.35 million, data from Yahoo Finance ‎shows. The ‎decrease of -0.75% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to ‎cover (short ratio) moved to while the shorted shares account for just 14.10% of the overall ‎float for ‎the stock.‎‎

Sage Therapeutics Inc.’s Biggest Shareholders: Who Owns Sage Therapeutics ‎Inc. ‎‎[SAGE]?

Filings by Fidelity Management & Research Co showed that the firm now holds a ‎total of ‎‎7,732,540 shares or roughly 14.86% of the outstanding SAGE shares. This means their shares ‎have ‎increased by 8,468 from the 7,732,540 the investor reportedly held in its prior 13-F filing. With ‎the ‎conclusion of the purchase, The Vanguard Group, Inc. updated stake is worth $329,515,942. Details ‎in ‎the latest 13F filings reveal that T. Rowe Price Associates, Inc. disposed off their -9.22% stake valued ‎at ‎‎$189,598,829 while D. E. Shaw & Co. LP added theirs at $182,488,560. During the last quarter, T. ‎Rowe ‎Price Associates, Inc. liquidated -260,018 of its shares in Sage Therapeutics Inc. while D. E. Shaw ‎& Co. ‎LP bought 340,910 shares. The BlackRock Fund Advisors’s holdings currently number 2,372,497 ‎shares ‎at $205244715.47. According to the firm’s last 13F report, Great Point Partners LLC shares in ‎the ‎company at filing stood at 1,966,688 shares, roughly $145,711,914.‎‎

SAGE Earnings Forecast For ‎The Current Quarter

Sage Therapeutics Inc. [SAGE] is expected ‎to report strong earnings results ‎for the quarter ending on Dec 2020. Consensus estimates give the ‎company expected revenues of ‎‎$55.34M and an earnings per share of -$0.45 for Dec 2020. Looking ‎further ahead, the company is ‎expected to report revenue of $174.85M at an EPS of $0.91 for Mar ‎‎2021. The estimates represent ‎upside of 311.40% and 60.40% in the company’s revenue and earnings ‎per share, respectively, on a ‎year-on-year basis.‎‎

Get the hottest stocks to trade every day before the ‎market opens 100% ‎free. Click here now. 

SAGE Earnings Estimates For ‎The Current ‎Year

For the financial year, Sage Therapeutics Inc. [NASDAQ:SAGE] is expected to ‎bring in ‎revenue of $57.75M. The returns are nearly $50.88 million higher than the company’s actual ‎revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -7.39, higher ‎than that ‎of FY19 by $5.99. Estimates put this year’s earnings growth at 44.80%, 60.40% for the next, ‎and at an ‎annual 41.40% over the next 5-year period. As for sales, forecasts are for an increase of ‎‎740.90% in the ‎current fiscal year and a further 311.40% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

For What Reason, Bemax Inc (BMXC) Stock Climbed 5%?

A stock of Bemax Inc surged 5.41% in the last session, closing at $0.0039. The 30-day average volume for the stock was 204.32M...

Why R. R. Donnelley (RRD) Stock Trading Higher In Pre-Market Trades? Here Is The Reason

R.R. Donnelley & Sons Company (RRD) stock has been surging 37.92% pre-market to $3.31 as of 08:18 a.m. EST, following the release of the...

Why Stock of MediaTechnics Corporation (OTC: MEDT) Skyrocketed 133%?

MediaTechnics Corporation (OTC: MEDT) skyrocketed +133.33% on Tuesday to close the trading at $0.0021. Per the week, the stock gained 50%, while for the...

Want to know about the Top 3 biotech stocks for 2021? Let’s find out

A technology to create and develop different products by using the biological systems, living organisms, and parts of this is called ‘Biotechnology’. A product...

Why Medifirst Solutions (MFST) Skyrocketed 159% on Monday? Here Is the Explanation

Medifirst Solutions Inc (OTC: MFST) stock skyrocketed on Monday recording a rise of 159.46% to $0.0096 at the previous close. Last week, the stock...

For What Reason, Bemax Inc (BMXC) Stock Climbed 5%?

A stock of Bemax Inc surged 5.41% in the last session, closing at $0.0039. The 30-day average volume for the stock was 204.32M...

What Is Driving Salarius Pharmaceuticals, Inc. (SLRX) Stock Up In Pre-Market Session?

Shares of biopharma company Salarius Pharmaceuticals, Inc. (SLRX) have been rising +16.58% to $2.25 (as of 09:07 a.m. EST) before the start of the...

Why R. R. Donnelley (RRD) Stock Trading Higher In Pre-Market Trades? Here Is The Reason

R.R. Donnelley & Sons Company (RRD) stock has been surging 37.92% pre-market to $3.31 as of 08:18 a.m. EST, following the release of the...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.